M
Michael R. Jacobs
Researcher at Penn State Milton S. Hershey Medical Center
Publications - 52
Citations - 2120
Michael R. Jacobs is an academic researcher from Penn State Milton S. Hershey Medical Center. The author has contributed to research in topics: Penicillin & Cefoxitin. The author has an hindex of 30, co-authored 52 publications receiving 2087 citations. Previous affiliations of Michael R. Jacobs include University Hospitals of Cleveland & Case Western Reserve University.
Papers
More filters
Journal ArticleDOI
Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers.
TL;DR: Although beta-lactamase positivity is on the increase in non-B.
Journal ArticleDOI
Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology.
TL;DR: Of the new compounds tested, RP 59500 and sparfloxacin show promise for the treatment of infections caused by penicillin-susceptible and -resistant pneumococci, and at a concentration equal to the MIC it was bactericidal within 3 h.
Journal ArticleDOI
Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes.
TL;DR: Agar dilution was used to compare the in vitro activity of CP 99,219 with those of ciprofloxacins, grepafloxacin, metronidazole, cefoxitin, piperacillin, and pipersacillin-tazobactam against 489 anaerobes.
Journal ArticleDOI
Activity of CP 99, 219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepaloxacin against penicillin-susceptible and -resistant pneumococci
Journal ArticleDOI
Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.
TL;DR: All four experimental quinolones as well as RP 59500 show promise for therapy of infections with penicillin-resistant and -susceptible pneumococci.